Radiopharm collaborates with Lantheus on theranostic agent

By AuntMinnie.com staff writers

August 4, 2022 -- Radiopharm Theranostics has entered a collaboration agreement with Lantheus to develop NM-01, a nanobody that can be labeled with radioisotopes to diagnose and treat tumors for theranostic applications.

NM-01 was developed using genetically engineered, camelid-derived, single-domain antibodies. Radiopharm has additionally acquired the imaging rights of NM-01 from NanoMab for the Chinese market and worldwide intellectual property rights for any therapeutic use.

Radiopharm will soon initiate a phase I therapeutic trial in Australian patients with programmed cell death ligand 1 (PD-L1) positive non-small cell lung cancer. Radiopharm and Lantheus have agreed to cross-reference each other's data to facilitate development plans for the PD-L1 assets, including the regulatory process with the U.S. Food and Drug Administration and other key regulatory agencies.


Copyright © 2022 AuntMinnie.com
 
Member Sign In:
MemberID or Email Address:  
Do you have a AuntMinnie.com password?
No, I want a free membership.
Yes, I have a password:  
Forgot your password?
Sign in using your social networking account:
Sign in using your social networking
account: